Compare YQ & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | TXMD |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 24.3M |
| IPO Year | 2020 | 2012 |
| Metric | YQ | TXMD |
|---|---|---|
| Price | $2.67 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 18.0K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.70 | $0.98 |
| 52 Week High | $6.45 | $2.95 |
| Indicator | YQ | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 44.11 |
| Support Level | $2.55 | $1.94 |
| Resistance Level | $3.68 | $2.05 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 70.16 | 20.79 |
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.